natgillin/translations-raw huggingface dataset:
Patients with glucose-galactose malabsorption should not take this medicine. 
Bolniki z motnjo malabsorpcije glukoze in galaktoze ne smejo jemati tega zdravila.
Elevated liver function tests were generally reversible on discontinuation of therapy and in some instances these tests normalised without interruption of therapy. 
Zvišani izvidi preiskav delovanja jeter so bili običajno reverzibilni po prenehanju terapije, v nekaterih primerih pa so se ti izvidi povrnili na normalo že brez prekinitve terapije.
Posaconazole was not genotoxic in in vitro and in vivo studies. 
Posakonazol ni bil genotoksičen v študijah in vitro in in vivo.
Your doctor will monitor your response and condition to determine how long Posaconazole SP needs to be given and whether any change is needed to your daily dose. 
Zdravnik bo spremljal vaš odziv in stanje in tako ugotovil, kako dolgo morate jemati zdravilo Posaconazole SP in ali je potrebna kakšna sprememba dnevnega odmerka.
No pharmacokinetic data are available from paediatric patients less than 8 years of age. 
Ni nobenih farmakokinetičnih podatkov za pediatrične bolnike, mlajše od 8 let.
The clinical response rates from the above study are shown in the Table 4 below. 
Vrednosti kliničnega odziva iz zgornje študije so prikazane v Preglednici 4 v nadaljevanju.
• Any problem with amounts of potassium, magnesium or calcium in your blood. 
• kakršnokoli motnjo v zvezi z vsebnostjo kalija, magnezija ali kalcija v krvi
The use of combination antifungal therapies should not decrease the efficacy of either posaconazole or the other therapies; however, there is currently no clinical evidence that combination therapy will provide an added benefit. 
Uporaba kombiniranih antimikotičnih terapij naj ne bi zmanjšala učinkovitosti posakonazola ali drugih terapij, vendar doslej ni kliničnih dokazov, da bo kombinirana terapija prinesla dodatno korist.
Overall Response Success by Species All mycologically confirmed Aspergillus spp.1 
Uspešnost po vrstah Vse mikološko potrjeno Aspergillus spp.
Additionally, twelve patients 13-17 years of age received 600 mg/day for prophylaxis of invasive fungal infections (Studies 316 and 1899). 
Poleg tega je dvanajst bolnikov, starih od 13 do 17 let, prejemalo 600 mg/dan za profilakso invazivnih glivičnih okužb (študiji 316 in 1899).
* During post-marketing surveillance severe hepatic injury with fatal outcome has been reported (see section 4.4). 
* V času spremljanja v obdobju trženja so poročali o hudi jetrni okvari s smrtnim izidom (glejte poglavje 4.4).
• Concomitant use with medicinal products known to prolong the QTc interval (other than those mentioned in section 4.3). 
• sočasno uporabo z zdravili, za katera je znano, da podaljšajo interval QTc (drugimi, ki so omenjena v poglavju 4.3).
The excretion of posaconazole in human breast milk has not been investigated. 
Izločanja posakonazola v materino mleko pri človeku niso raziskovali.
Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. 
Odpornost na zdravilo je opredeljena kot napredovanje okužbe ali odsotnost izboljšanja po najmanj 7-dnevni predhodni učinkoviti antimikotični terapiji s terapevtskimi odmerki.
The primary efficacy variable was the clinical success rate (defined as cure or improvement) after 14 days of treatment. 
Primarni parameter učinkovitosti je bila klinična uspešnost (opredeljena kot ozdravitev ali izboljšanje stanja) po 14 dneh zdravljenja.
Name and address of the manufacturer responsible for batch release Schering-Plough S.A., 2, rue Louis Pasteur; 14200 Hérouville St Clair, France 
Ime in naslov izdelovalca, odgovornega za sproščanje serije Schering-Plough S.A., 2, rue Louis Pasteur; 14200 Hérouville St Clair, Francija
Posaconazole is slowly absorbed and slowly eliminated with a large apparent volume of distribution (1,774 litres) and is highly protein bound (> 98 %), predominantly to serum albumin. 
Posakonazol se počasi absorbira in počasi izloča, z velikim navideznim porazdelitvenim volumnom (1774 litrov) in se v veliki meri veže na beljakovine (> 98 %), predvsem na serumski albumin.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER SP Europe 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM SP Europe
Any product remaining four weeks after opening the bottle should be discarded. 
Morebitno količino zdravila, ki preostane štiri tedne po odprtju stekleničke, zavrzite.
d: All randomized e: All treated 
vsi randomizirani e:
The external control group included 86 patients treated with available therapy (as above) mostly at the same time and at the same sites as the patients treated with posaconazole. 
V zunanji kontrolni skupini je bilo 86 bolnikov, ki so bili zdravljeni z razpoložljivimi zdravili (kot zgoraj), in sicer večinoma ob istem času in na istih mestih kot bolniki, zdravljeni s posakonazolom.
Marketing Authorisation Holder: SP Europe 
Imetnik dovoljenja za promet z zdravilom: SP Europe
New diagnosis of acute myelogenous leukemia was the most common underlying condition (435/602, [72 %]). 
Najpogostejša osnovna bolezen je bila novodiagnosticirana akutna mieloična levkemija (435/602, [72 %]).
Safety and efficacy in paediatric patients below the age of 18 years have not been established. 
Varnost in učinkovitost zdravila pri pediatričnih bolnikih, mlajših od 18 let, še nista bili ugotovljeni.
Therefore trough concentrations that fall in the upper part of the usual therapeutic range should be targetted and careful attention should be paid to clinical signs and symptoms, laboratory parameters and tissue biopsies. 
Zato bi se morali truditi, da bodo najnižje koncentracije sirolimusa ves čas v zgornjem delu običajnega terapevtskega razpona in pozorno spremljati klinične znake in simptome pri bolniku ter laboratorijske parametre in izvide tkivnih biopsij.
In Study 316, overall mortality was similar (POS, 25 %; FLU, 28 %); however, the proportion of IFIrelated deaths was significantly lower in the POS group (4/301) compared with the FLU group (12/299; P= 0.0413). 
V študiji 316 je bila skupna umrljivost podobna (POS, 25 %; FLU, 28 %), vendar je bil odstotek smrtnih primerov v povezavi z IFI bistveno manjši v skupini, ki je prejemala POS (4/301), kot pri skupini, ki je prejemala FLU (12/299; p= 0,0413).
This medicinal product contains approximately 1.75 g of glucose per 5 ml of suspension. 
To zdravilo vsebuje približno 1,75 g glukoze v 5 ml peroralne suspenzije.
Reproduction, peri- and postnatal development studies were conducted in rats. 
Pri podganah so bile opravljene študije razmnoževanja ter peri- in postnatalnega razvoja.
The microbiological data suggest that posaconazole is active against Rhizomucor, Mucor, and Rhizopus, however the clinical data are currently too limited to assess the efficacy of posaconazole against these causative agents. 
Mikrobiološki podatki kažejo, da je posakonazol učinkovit proti vrstam Rhizomucor, Mucor in Rhizopus, vendar so klinični podatki zaenkrat še preveč omejeni, da bi lahko ocenili učinkovitost posakonazola proti tem povzročiteljem okužb.
Most of the cases of aspergillosis were considered to be refractory to prior therapy in both the posaconazole group (88 %) and in the external control group 
Večino primerov aspergiloze so ocenili za odporne na predhodno terapijo, tako v skupini za posakonazol (88 %) kot v zunanji kontrolni skupini (79 %).
Posaconazole inhibits the enzyme lanosterol 14α-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis. 
Posakonazol zavira encim lanosterol 14α-demetilazo (CYP51), ki katalizira nujno stopnjo v biosintezi ergosterola.
• Sulfonylureas such as glipizide (used to treat high blood sugar). 
• sulfonilureje, kot je glipizid (ki jih uporabljamo za zdravljenje zvišanega sladkorja v krvi).
Posaconazole must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus. 
Zdravila posakonazol ne smete uporabljati med nosečnostjo, razen če korist za mater očitno odtehta potencialno tveganje za plod.
Please see the section “Taking other medicines” for information on other medicines which may interact with Posaconazole SP. 
Glejte poglavje “Jemanje drugih zdravil”, kjer so navedeni podatki o drugih zdravilih, ki imajo lahko medsebojno delovanje z zdravilom Posaconazole SP.
Important information about some of the ingredients of Posaconazole SP Posaconazole SP contains approximately 1.75 g of glucose per 5 ml of suspension. 
Pomembne informacije o nekaterih sestavinah zdravila Posaconazole SP Posaconazole SP vsebuje približno 1,75 g glukoze na 5 ml peroralne suspenzije.
B-1180 Bruxelles, Belgium 
B-1180 Bruxelles, Belgija
Prevention of serious Fungal Infections 
Preprečevanje resnih glivičnih okužb
Coadministration of posaconazole with sirolimus is not recommended and should be avoided whenever possible. 
Sočasna uporaba posakonazola s sirolimusom ni priporočljiva in se ji morate izogibati, kadarkoli je to mogoče.
In Study 1899, a significant decrease in all cause mortality in favour of posaconazole was observed [POS 49/304 (16 %) vs. FLU/ITZ 67/298 (22 %) p= 0.048]. 
V študiji 1899 so opazili bistveno zmanjšanje umrljivosti iz vseh vzrokov v prid posakonazolu [POS 49/304 (16 %) v primerjavi s FLU/ITZ 67/298 (22 %) p= 0,048].
Tell your doctor if you are or think you are pregnant before you start to take Posaconazole SP. Do not use Posaconazole SP during pregnancy unless you are told by your doctor. 
Če ste noseči ali mislite, da ste noseči, morate to povedati svojemu zdravniku pred začetkom jemanja zdravila Posaconazole SP. Ne jemljite zdravila Posaconazole SP med nosečnostjo, razen če vam ga predpiše vaš zdravnik.
There are other medicines that can sometimes be given while you are taking Posaconazole SP but special care may be needed. 
Obstajajo pa druga zdravila, ki jih lahko včasih uporabljamo med jemanjem zdravila Posaconazole SP, vendar je v tem primeru lahko potrebna posebna previdnost.
Proportion (%) of patients with proven/probable IFIs On-treatment period b 
Odstotek (%) bolnikov z dokazanimi oziroma verjetnimi IFI Obdobje na terapiji b
Effects of posaconazole on other medicinal products: 
Učinki posakonazola na druga zdravila:
The mean duration of therapy was 80 days for posaconazole and 77 days for fluconazole. 
Srednja dolžina zdravljenja je bila 80 dni za posakonazol in 77 dni za flukonazol.
The duration of therapy is based on recovery from neutropenia or immunosuppression. 
Trajanje terapije je odvisno od okrevanja po nevtropeniji ali imunosupresiji.
Sixteen patients 8-17 years of age were treated with 800 mg/day in a study for invasive fungal infections. 
Šestnajst bolnikov, starih od 8 do 17 let, so zdravili z 800 mg/dan v študiji uporabe zdravila pri invazivnih glivičnih okužbah.
allergic reaction hypersensitivity reaction 
alergijske reakcije preobčutljivostne reakcije
Accidental overdose was noted in one patient who took 1,200 mg twice a day for 3 days. 
Nenamerno preveliko odmerjanje so ugotovili pri enem bolniku, ki je 3 dni jemal odmerek 1200 mg dvakrat na dan.
As observed with other azole antifungal agents, these effects on reproduction were considered to be due to a treatment-related effect on steroidogenesis. 
Kot so opažali tudi pri drugih azolskih antimikotikih, so menili, da so ti učinki na razmnoževanje pričakovani z učinkom terapije na steroidogenezo.
There is no information on the effect of Posaconazole SP on the ability to drive and use machines. 
Ni podatkov o vplivu zdravila Posaconazole SP na sposobnost vožnje in upravljanja s stroji.
• Some medicines used to treat or prevent fits, such as phenytoin, carbamazepine, phenobarbital, 
• nekatera zdravila, ki jih uporabljamo za zdravljenje ali preprečevanje epileptičnih napadov, na primer fenitoin, karbamazepin, fenobarbital, primidon.
Please return the bottle containing any left over suspension to your pharmacist. 
Stekleničko z morebitno preostalo suspenzijo vrnite nazaj v lekarno.
At exposures lower than those obtained at therapeutic doses in humans, posaconazole caused skeletal variations and malformations, dystocia, increased length of gestation, reduced mean litter size and postnatal viability. 
Pri izpostavljenostih, manjših od tistih, ki so jih dobili pri terapevtskih odmerkih pri človeku, je posakonazol povzročil spremembe skeleta in malformacije, distocijo, podaljšano dolžino gestacije ter zmanjšano srednje število mladičev in postnatalno življenjsko sposobnost.
Prophylaxis of Invasive Fungal Infections (IFIs) (Studies 316 and 1899) Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections. 
Profilaksa invazivnih glivičnih okužb (IFI) (študiji 316 in 1899) Opravljeni sta bili dve randomizirani, kontrolirani študiji profilakse pri bolnikih z velikim tveganjem za nastanek invazivnih glivičnih okužb.
PHARMACEUTICAL FORM AND CONTENTS One bottle of 105 ml of oral suspension Measuring spoon 
FARMACEVTSKA OBLIKA IN VSEBINA Ena 105 ml steklenička peroralne suspenzije Odmerna žlička
A key secondary endpoint was the incidence of proven/probable IFIs during the on-treatment period (first dose to last dose of study medicinal product + 7 days). 
Ključni sekundarni končni rezultat je bila incidenca dokazane oziroma verjetne IFI v obdobju na terapiji (od prvega odmerka do zadnjega odmerka proučevanega zdravila + 7 dni).
• Efavirenz, which is used to treat HIV infection. 
• efavirenz, ki ga uporabljamo za zdravljenje okužbe z virusom HIV.
LIST OF EXCIPIENTS Contains also liquid glucose. 
SEZNAM POMOŽNIH SNOVI Vsebuje tudi tekočo glukozo.
The excreted metabolites in urine and faeces account for approximately 17 % of the administered radiolabelled dose. 
Presnovki, izločeni v seč in blato, zajemajo približno 17 % danega radioaktivno označenega odmerka.
Digoxin: Administration of other azoles has been associated with increases in digoxin levels. 
Digoksin: Dajanje drugih azolov je bilo povezano s povečanjem koncentracije digoksina.
Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). 
V spremljanje bolnika vključite tudi laboratorijsko oceno delovanja jeter (še posebej preiskave delovanja jeter in določanje bilirubina).
Monitoring of glucose concentrations is recommended in diabetic patients. 
Pri diabetikih je priporočljivo spremljanje koncentracije glukoze.
• A weakness of the heart muscle or heart failure 
• šibkost srčne mišice ali srčno popuščanje
For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with Posaconazole SP should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm 
Pri bolnikih z akutno mieloično levkemijo ali mielodisplastičnimi sindromi je treba profilakso z zdravilom Posaconazole SP začeti več dni pred pričakovanim nastopom nevtropenije in naj traja še 7 dni po zvišanju števila nevtrofilcev nad 500 celic/mm
Ergot alkaloids: Posaconazole may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine), which may lead to ergotism. 
Ergot alkaloidi: Posakonazol lahko poveča plazemsko koncentracijo ergot alkaloidov (ergotamina in dihidroergotamina), kar lahko vodi do ergotizma.
Co-administration with ergot alkaloids (see section 4.5). 
Sočasna uporaba z ergot alkaloidi (glejte poglavje 4.5).
Renal clearance is a minor elimination pathway, with 14 % of the radiolabelled dose excreted in urine (< 0.2 % of the radiolabelled dose is parent compound). 
Ledvični očistek je bila manj pomembna pot izločanja, pri čemer se je 14 % radioaktivno označenega odmerka izločilo s sečem (< 0,2 % radioaktivno označenega odmerka je bila matična spojina).
Rarely, more severe hepatic reactions with fatal outcomes have been reported. 
O hujših jetrnih učinkih s smrtnim izidom so poročali redko.
Patients who have severe diarrhoea or vomiting should be monitored closely for breakthrough fungal infections. 
Bolnike, ki imajo hudo drisko ali bruhajo, je treba skrbno spremljati, da ugotovite morebitne glivične okužbe.
In addition to the medicines named above that must not be taken with posaconazole because of the risk of heart rhythm disturbances, there are other medicines that carry a risk of rhythm problems that may be greater when they are taken with posaconazole. 
Poleg zgoraj navedenih zdravil, ki jih zaradi tveganja za pojav motenj srčnega ritma ne smete jemati skupaj s posakonazolom, obstajajo tudi druga zdravila s tveganjem za motnje ritma, ki se lahko poveča pri njihovem jemanju skupaj s posakonazolom.
• cisapride (used to treat stomach problems) 
• cisaprid (ki ga uporabljamo za zdravljenje želodčnih težav)
Similarly, in the prophylaxis studies, the mean steady-state posaconazole average concentration (Cav) was comparable among ten adolescents (13-17 years of age) to Cav achieved in adults (≥ 18 years of age). 
Podobno je bila v študijah profilaktične uporabe zdravila srednja vrednost povprečne koncentracije posakonazola v stanju dinamičnega ravnovesja (Cav) pri desetih mladostnikih (starih od 13 do 17 let) podobna vrednosti Cav, doseženi pri odraslih (starih ≥ 18 let).
The mean duration of therapy was 29 days for posaconazole and 25 days for fluconazole/itraconazole. 
Srednja dolžina zdravljenja je bila 29 dni za posakonazol in 25 dni za flukonazol oziroma itrakonazol.
• Vincristine, vinblastine and other vinca alkaloids (used to treat cancer) 
• vinkristin, vinblastin in drugi vinka alkaloidi (ki jih uporabljamo za zdravljenje raka)
• pimozide (used to treat symptoms of Tourette's disorder) 
• pimozid (ki ga uporabljamo za zdravljenje simptomov Tourettovega sindroma)
Psychiatric disorders Rare: 
Psihiatrične motnje Redki:
Posaconazole SP can be used to prevent fungal infections in patients whose immune systems may be weakened due to other medicines or diseases. 
Zdravilo Posaconazole SP lahko uporabljamo za preprečevanje glivičnih okužb pri bolnikih, katerih imunski sistem je lahko oslabljen zaradi jemanja drugih zdravil ali zaradi bolezni.
Proportion (%) of patients with proven/probable Aspergillosis On-treatment periodb d e 
Kontrolna skupinaa Odstotek (%) bolnikov z dokazano oziroma verjetno aspergilozo Obdobje na terapijib d e
105 ml of oral suspension in a 123 ml bottle (glass amber type IV) closed with a plastic child-resistant cap (polypropylene) and a measuring spoon (polystyrene) with 2 graduations: 2.5 ml and 5 ml. 
105 ml peroralne suspenzije v 123 ml steklenički (rjavo steklo tipa IV), zaprti s plastično za otroke varno zaporko (iz polipropilena) in odmerno žličko (iz polistirena) z 2 oznakama: 2,5 ml in 5 ml.
menstrual disorder breast pain 
menstrualne motnje bolečine v dojkah
If you are not able to take food or nutritional supplement, your doctor will tell you to take 200 mg (one 5 ml spoonful) four times a day. 
Če ne morete jesti hrane ali uživati prehranskih dodatkov, vam bo zdravnik predpisal odmerek 200 mg (eno 5 ml žličko) štirikrat na dan.
Increased systolic and arterial blood pressures (up to 29 mm-Hg) were seen in rats and monkeys at systemic exposures 1.4-fold and 4.6-fold greater, respectively, than those achieved with therapeutic doses. 
Zvišan sistolični in arterijski krvni tlak (do 29 mm Hg) so opažali pri podganah oz. opicah pri sistemskih izpostavljenostih, ki so bile 1,4-krat oz. 4,6-krat večje od tistih, ki jih dosežemo pri terapevtskih odmerkih.
Posaconazole SP belongs to a group of medicines called triazole antifungal agents. 
Posaconazole SP sodi v skupino zdravil, ki se imenujejo triazolska protiglivična zdravila (antimikotiki).
Posaconazole SP is indicated for use in the treatment of the following fungal infections in adults (see section 5.1): 
Posaconazole SP je indiciran za uporabo pri zdravljenju naslednjih glivičnih okužb pri odraslih (glejte poglavje 5.1):
b: In 1899 this was the period from randomization to last dose of study medicinal product plus 7 days; in 316 it was the period from first dose to last dose of study medicinal product plus 7 days. 
V študiji 1899 je šlo tu za obdobje od randomizacije do zadnjega odmerka proučevanega zdravila plus 7 dni, v študiji 316 pa je bilo to obdobje od prvega odmerka do zadnjega odmerka proučevanega zdravila plus 7 dni.
Posaconazole SP is also indicated for prophylaxis of invasive fungal infections in the following patients: 
Posaconazole SP je indiciran tudi za profilakso invazivnih glivičnih okužb pri naslednjih bolnikih:
Posaconazole has been shown in vitro to be active against the following microorganisms: Aspergillus species (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus. 
Pokazali so, da posakonazol in vitro deluje proti naslednjim mikroorganizmom: Aspergillus sp. (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida sp. (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi in vrste Fusarium, Rhizomucor, Mucor in Rhizopus.
However, as posaconazole is not significantly renally eliminated, an effect of severe renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended. 
Ker pa se posakonazol ne izloča v bistveni meri skozi ledvica, ni pričakovati vpliva hude ledvične okvare na farmakokinetiko posakonazola in ni priporočeno nikakršno prilagajanje odmerka.
In subjects with severe renal impairment (n=6, Cl cr < 20 ml/min/1.73 m2), the AUC of posaconazole was highly variable [> 96 % CV (coefficient of variance)] compared to other renal groups [< 40 % CV]. 
Pri preiskovancih s hudo ledvično okvaro (n=6, Cl kr < 20 ml/min/1,73 m2) je bila vrednost AUC posakonazola močno spremenljiva [> 96 % CV (koeficient variance)] v primerjavi z drugimi kategorijami ledvične funkcije [< 40 % CV].
• Medicines used to decrease stomach acid such as cimetidine and ranitidine or omeprazole and similar medicines that are called proton pump inhibitors. 
• zdravila, ki se uporabljajo za zmanjševanje količine želodčne kisline, kot so cimetidin in ranitidin ali omeprazol ter podobna zdravila, ki jih imenujemo zaviralci protonske črpalke.
Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders. 
Med 18 bolniki, ki niso prenašali amfotericina B ali itrakonazola ali ki so imeli okužbe, odporne na amfotericin B ali itrakonazol, so jih sedem uvrstili med odzivne na zdravljenje.
In the small number of subjects studied who had hepatic impairment, there was an increase in exposure and half-life with a decrease in hepatic function (see sections 4.4 and 5.2). 
Pri majhnem številu preiskovancev iz študij, ki so imeli jetrno okvaro, je prišlo do povečanja izpostavljenosti zdravilu in razpolovne dobe zdravila, z zmanjšanjem delovanja jeter (glejte poglavji 4.4 in 5.2).
The addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated with increases in plasma bilirubin levels. 
Dodatek posakonazola med zdravljenjem z atazanavirjem oziroma z atazanavirjem in ritonavirjem je bil povezan s povečanjem plazemske koncentracije bilirubina.
In a study with small number of subjects (n=12) who had hepatic impairment, there was an increase in exposure associated with prolongation of half-life in hepatic impaired patients (26.6, 35.3, and 46.1 hours for the mild, moderate and severe groups, respectively compared to 22.1 hours in subjects with normal hepatic function). 
V študiji pri majhnem številu preiskovancev (n=12), ki so imeli jetrno okvaro, so ugotovili povečanje izpostavljenosti zdravilu, povezano s podaljšanjem razpolovne dobe pri bolnikih z jetrno okvaro (26,6 ur za blago, 35,3 ur za zmerno in 46,1 ur za hudo jetrno okvaro, v primerjavi z 22,1 ur pri preiskovancih z normalnim delovanjem jeter).